Safety Study of XT-150 in Participants With ALS

ClinicalTrials.gov ID

NCT06704347

Lead Sponsor

Xalud Therapeutics, Inc.INDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 1

Enrollment

8Estimated

Last Update Posted

Jul 29, 2026Actual

Start Date

Mar 2027Estimated

Primary Completion Date

Jun 2028Estimated

Completion Date

Jun 2028Estimated

Official Title

A Phase 1, Open-Label Study Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Biomarkers of Single Ascending Dose Regimens of XT-150 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Brief Summary

This is a Phase 1, open-label, multi-center safety study of XT-150 in adult participants with Amyotrophic Lateral Sclerosis (ALS).

Participants providing informed consent and meeting all study eligibility criteria will be enrolled in the study and will receive a single injection of XT-150 at the Baseline visit. Follow-up visits will occur over 180 days (6 months) after the injection.

8 participants (4 participants per dose level) will be enrolled sequentially in up to 2 ascending, single dose cohorts: Cohort 1: 1.5 mg XT-150 Cohort 2: 4.5 mg XT-150

Detailed Description

The main questions this study is aiming to answer are:

• What adverse events are reported during this study? An adverse event is any "side effect" that participants have during a study. Adverse events may or may not be caused by XT-150. The study doctors will check participants' ALS and general health throughout the trial.
• Does XT-150 have any effects on participants' physical examination findings, vital signs, or laboratory values?

In addition to evaluating the safety of XT-150, this study will also collect samples to provide information on the following:

• The levels of XT-150 in your body
• The effect of XT-150 on cytokines including interleukin (IL)-10
• The effect of XT-150 on relevant ALS biomarkers such as Neurofilament Light (NfL)

In addition, ALS functional score, breathing capacity and strength will be collected over the course of the study.

• Amyotrophic Lateral Sclerosis (ALS)

• XT-150

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Key Inclusion Criteria:

• Adults between 18 and 80 years of age
• Male or female, if of childbearing potential or sexually active, strict contraception required
• Have ALS diagnosed by a doctor (specifically, sporadic or familial ALS diagnosed as clinically probable, lab-supported probable or definite ALS defined by the El Escorial criteria)
• Have had symptoms of ALS (muscle weakness) within 36 months of starting this study
• Have the ability to slowly exhale a volume of air at least 60% of what is expected for the participant's sex, height and age
• Have not received treatment for ALS or are currently on a stable dose of an approved treatment for ALS. Patients currently receiving Tofersen are not eligible.
• Able to receive the study injection intrathecally, determined by the study doctor
• Able to undergo the study procedures and adhere to the study visit schedule at the time of study entry, with an estimated life expectancy of 6 months or greater

Key Exclusion Criteria:

• Have an implanted shunt to drain cerebrospinal fluid (CSF) or an implanted CNS catheter
• Have an implanted of diaphragm pacing system
• Tracheostomy
• History or current diagnosis of cardiac conditions or ECG abnormalities indicating significant risk of safety for participants in the study
• History or current diagnosis of respiratory conditions such as COPD
• History or current diagnosis of cancer, chemical meningitis, HIV, Hep B, Hep C, uncontrolled diabetes
• Presence of an autoimmune condition (for example, rheumatoid arthritis or lupus) requiring treatment or immunodeficiency
• Clinical or laboratory evidence of hepatic or renal disease/injury.
• Taking any prohibited medications
• Women who are pregnant or nursing
• Use of any investigational drugs or devices within 30 days or 5 half-lives of the study agent (whichever is longer). Exception: Observational, non-interventional clinical studies are allowed in the opinion of the study doctor.
• Any other condition that the study doctor feels could compromise the participant's safety, ability to communicate with the study staff, or the quality of the data

Primary Purpose

Treatment

Allocation

Non-Randomized

Interventional Model

Sequential Assignment

Masking

None (Open Label)

Lead Sponsor

Xalud Therapeutics, Inc.INDUSTRY

mstotla1@hfhs.org313-916-3359

• AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

  NCT06665165

  RecruitingInterventionalPhase 1Updated Apr 14, 2026
• Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)

  NCT04569435

  CompletedInterventionalPhase 2Updated Jan 6, 2025
• A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis

  NCT07660614

  RecruitingInterventionalPhase 1Phase 2Updated Aug 18, 2026
• Multiple Doses of AT-1501-A201 in Adults With ALS

  NCT04322149

  CompletedInterventionalPhase 2Updated Jun 28, 2023
• A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

  NCT06441682

  Active, not recruitingInterventionalPhase 2Updated Apr 8, 2026
• Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

  NCT04987671

  Unknown statusInterventionalPhase 1Phase 2Updated Jul 24, 2023